SNTI Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Senti Biosciences Holdings Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerSNTI

Market Cap30.9M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Senti Biosciences Holdings Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for SENTI-202 (Phase 1) using Cell Therapy.

Pipeline

Asset	Indication	Modality	Stage	Public Note
SENTI-202	n/a	Cell Therapy	Phase 1	Public pipeline row
IL15	n/a	Cell Therapy	n/a	Public pipeline row
SENTI-301A	n/a	Cell Therapy	Preclinical	Public pipeline row
SENTI-401	n/a	Cell Therapy	n/a	Public pipeline row
CD33	Precise Targeting of AML	Cell Therapy	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

asset_name | CD33
asset_name | CD33
indication | Precise Targeting of AML
indication | Precise Targeting of AML
modality | Cell Therapy

Want the full SNTI research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.